Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Akari Therapeutics ( (AKTX) ) has issued an update.
On June 30, 2025, Akari Therapeutics held its Annual General Meeting where shareholders approved all matters presented, including the election of director nominees and the ratification of BDO USA, P.C. as the independent registered public accounting firm. The meeting also authorized an increase in the number of shares available under the 2023 Plan and approved compensation-related resolutions, reflecting strong shareholder support for the company’s strategic direction and governance.
The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Average Trading Volume: 24,113
Technical Sentiment Signal: Sell
Current Market Cap: $33.47M
Learn more about AKTX stock on TipRanks’ Stock Analysis page.